You are here

Home » Non-selective Cannabinoid Receptor Agonists » CP 55,940


CP 55,940

  ( 50 citations )    
Product Datasheet
Catalog Number:0949
Chemical Name:(-)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol
Product Details
Citations (50)
Supplemental Products
Reviews
Biological Activity
Cannabinoid agonist which is considerably more potent than Δ9-THC in both behavioral tests and receptor binding assays. Displays high and roughly equal affinity for both central and peripheral cannabinoid receptors (Ki = 0.6 - 5.0 and 0.7 - 2.6 nM at CB1 and CB2 respectively; EC50 values are 0.2, 0.3 and 5 nM at CB1, CB2 and GRP55 respectively).
Technical Data
  • M.Wt:
    376.58
  • Formula:
    C24H40O3
  • Solubility:
    Soluble to 100 mM in ethanol and to 100 mM in DMSO
  • Purity:
    >98
  • Storage:
    Store at -20°C
  • CAS No:
    83002-04-4
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis. All Tocris products are intended for laboratory research use only.
Additional Information
Licensing Caveats:
Sold for research purposes under agreement from Pfizer Inc.
Product Datasheets
SDS
COA view current batch
 or select another batch:
Citations:

The citations listed below are publications that use Tocris products. Selected citations for CP 55,940 include:

50 Citations: Showing 1 - 10
Filter your results:

  1. Characterization of structurally novel G protein biased CB1 agonists: implications for drug development.
    Authors: Ford
    Pharmacol Res  2017;125:161
  2. Cannabinoid receptor-specific mechanisms to alleviate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation.
    Authors: Vincent Et al.
    Haematologica  2016;101:566
  3. (4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride (LDK1229): a new cannabinoid CB1 receptor inverse agonist from the class of benzhydryl piperazine analogs.
    Authors: Mahmoud Et al.
    Mol Pharmacol  2015;87:197
  4. Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist.
    Authors: Presley Et al.
    Eur J Pharmacol  2015;3:e00159
  5. Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
    Authors: Mounsey Et al.
    Pharmacol Res Perspect  2015;273:36
  6. Flavanones from Miconia prasina.
    Authors: Tarawneh Et al.
    Phytochem Lett  2014;7:130
  7. Potential upstream regulators of cannabinoid receptor 1 signaling in prostate cancer: a Bayesian network analysis of data from a tissue microarray.
    Authors: Häggström Et al.
    J Biol Chem  2014;74:1107
  8. The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys.
    Authors: Hruba and McMahon
    Br J Pharmacol  2014;727:35
  9. Prefrontal deficits in a murine model overexpressing the down syndrome candidate gene dyrk1a.
    Authors: Thomazeau Et al.
    J Neurosci  2014;34:1138
  10. Analgesic effect of a mixed T-type channel inhibitor/CB2 receptor agonist.
    Authors: Gadotti Et al.
    Mol Pain  2013;9:32
  11. CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity.
    Authors: Baillie Et al.
    Mol Pharmacol  2013;83:322
  12. Long-term CB1 receptor blockade enhances vulnerability to anxiogenic-like effects of cannabinoids.
    Authors: Tambaro Et al.
    Neuropharmacology  2013;70:268
  13. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen.
    Authors: Prather Et al.
    Biochem Biophys Res Commun  2013;441:339
  14. Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB1 receptors: implications for schizophrenia.
    Authors: Seillier Et al.
    Eur J Pharmacol  2013;38:1816
  15. Novel insights into CB1 cannabinoid receptor signaling: a key interaction identified between the extracellular-3 loop and transmembrane helix 2.
    Authors: Marcu Et al.
    J Pharmacol Exp Ther  2013;345:189
  16. Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.
    Authors: Rajasekaran Et al.
    Toxicol Appl Pharmacol  2013;269:100
  17. Real-time characterization of cannabinoid receptor 1 (CB1 ) allosteric modulators reveals novel mechanism of action.
    Authors: Cawston Et al.
    Br J Pharmacol  2013;170:893
  18. Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors.
    Authors: Marini Et al.
    Br J Pharmacol  2013;169:887
  19. Working memory- and anxiety-related behavioral effects of repeated nicotine as a stressor: the role of cannabinoid receptors.
    Authors: Hayase
    BMC Neurosci  2013;14:20
  20. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.
    Authors: Brents Et al.
    Biochem Pharmacol  2012;83:952
  21. CB1 receptor autoradiographic characterization of the individual differences in approach and avoidance motivation.
    Authors: Laricchiuta Et al.
    PLoS One  2012;7:e42111
  22. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
    Authors: Chimalakonda Et al.
    Drug Metab Dispos  2012;40:2174
  23. AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor.
    Authors: Bolognini Et al.
    Br J Pharmacol  2012;165:2561
  24. A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury.
    Authors: Horváth Et al.
    J Physiol  2012;165:2462
  25. Mouse models for studying pain in sickle disease: effects of strain, age, and acuteness.
    Authors: Cain Et al.
    Br J Haematol  2012;156:535
  26. Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands.
    Authors: You Et al.
    Mol Pain  2011;7:89
  27. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity.
    Authors: Brents Et al.
    PLoS One  2011;6:e21917
  28. Convulsant doses of a dopamine D1 receptor agonist result in Erk-dependent increases in Zif268 and Arc/Arg3.1 expression in mouse dentate gyrus.
    Authors: Gangarossa Et al.
    PLoS One  2011;6:e19415
  29. Cannabinoids attenuate hippocampal γ oscillations by suppressing excitatory synaptic input onto CA3 pyramidal neurons and fast spiking basket cells.
    Authors: Holderith Et al.
    Br J Pharmacol  2011;589:4921
  30. Symptom-relieving and neuroprotective effects of the phytocannabinoid △9-THCV in animal models of Parkinson's disease.
    Authors: García Et al.
    J Cell Mol Med  2011;163:1495
  31. A putative 'pre-nervous' endocannabinoid system in early echinoderm development.
    Authors: Buznikov Et al.
    J Biol Chem  2010;32:43101
  32. Location, structure, and dynamics of the synthetic cannabinoid ligand CP-55,940 in lipid bilayers.
    Authors: Kimura Et al.
    Biophys J  2009;96:4916
  33. Genetic and pharmacological manipulations of the CB(1) receptor alter ethanol preference and dependence in ethanol preferring and nonpreferring mice.
    Authors: Vinod Et al.
    Synapse  2008;62:574
  34. Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling.
    Authors: Georgieva Et al.
    Neuropsychopharmacology  2008;581:19
  35. Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction.
    Authors: Kapur Et al.
    J Pharmacol Exp Ther  2008;325:341
  36. MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models.
    Authors: Naguib Et al.
    Br J Pharmacol  2008;155:1104
  37. Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs.
    Authors: Giannini Et al.
    Prostate  2008;12:2381
  38. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
    Authors: Pertwee Et al.
    Br J Pharmacol  2007;150:586
  39. S-nitrosothiols modulate G protein-coupled receptor signaling in a reversible and highly receptor-specific manner.
    Authors: Kokkola Et al.
    BMC Cell Biol  2005;6:21
  40. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation.
    Authors: Ehrhart Et al.
    J Neuroinflammation  2005;2:29
  41. Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.
    Authors: Thomas Et al.
    Br J Pharmacol  2005;146:917
  42. Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor.
    Authors: Savinainen Et al.
    Br J Pharmacol  2005;145:636
  43. The endocannabinoid 2-arachidonylglycerol decreases the immunological activation of Guinea pig mast cells: involvement of nitric oxide and eicosanoids.
    Authors: Vannacci Et al.
    J Pharmacol Exp Ther  2004;311:256
  44. Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716.
    Authors: Hilairet Et al.
    Exp Neurol  2003;278:23731
  45. An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors.
    Authors: Savinainen Et al.
    Br J Pharmacol  2003;140:1451
  46. Cannabinoid receptor-independent inhibition by cannabinoid agonists of the peripheral 5-HT3 receptor-mediated von Bezold-Jarisch reflex.
    Authors: Godlewski Et al.
    Br J Pharmacol  2003;138:767
  47. Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site.
    Authors: Barann Et al.
    Br J Pharmacol  2002;137:589
  48. Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens.
    Authors: Christopoulos Et al.
    Br J Pharmacol  2001;132:1281
  49. The endogenous cannabinoid agonist, anandamide stimulates sensory nerves in guinea-pig airways.
    Authors: Tucker Et al.
    Br J Pharmacol  2001;132:1127
  50. The actions of some cannabinoid receptor ligands in the rat isolated mesenteric artery.
    Authors: White and Hiley
    Br J Pharmacol  1998;125:533
Expand to show all Citations

FAQs

No product specific FAQs exist for this product, however you may

View all Small Molecule FAQs

Have you used CP 55,940?

Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.

Tocris Bioscience is the leading supplier of novel and exclusive tools for life science research with over 30 years' experience in the industry. Tocris is a Bio-Techne brand.

Order Details

Contact Us to Order
reload

Feedback

Customer Information
You May Also Like
 
Human Cannabinoid R2/CB2/CNR2 (NP_001832) VersaClone cDNA
 
Human Cannabinoid R1/CB1/CNR1 (NP_057167) VersaClone cDNA
 
Mouse Cannabinoid R1/CB1/CNR1 (NP_031752) VersaClone cDNA
 
Rat Cannabinoid R1/CB1/CNR1 (NP_036916) VersaClone cDNA
 
Mouse Cannabinoid R2/CB2/CNR2 (NP_034054) VersaClone cDNA
 
Rat Cannabinoid R2/CB2/CNR2 (NP_001157614) VersaClone cDNA
Calculators

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

R&D Systems Guarantee